Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorpheniramine + pseudoephedrine is an oral combination drug consisting of a **first-generation antihistamine** (chlorpheniramine) and a **sympathomimetic decongestant** (pseudoephedrine). - **Chlorpheniramine** antagonizes the **histamine H1 receptor**, blocking the action of endogenous histamine to relieve symptoms such as sneezing, itching, watery eyes, and runny nose associated with allergies or the common cold. - **Pseudoephedrine** acts as an agonist at adrenergic receptors, causing vasoconstriction in the nasal mucosa, thereby reducing nasal congestion. This combination is used for **symptomatic relief** of upper respiratory allergies (such as hay fever) and common cold symptoms, including nasal congestion, sneezing, runny or stuffy nose, and itchy or watery eyes. It does not treat the underlying cause of symptoms or shorten the duration of illness. It is available in multiple over-the-counter formulations[5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorpheniramine + pseudoephedrine.